Published date: 23 December 2021

Last edited date: 19 January 2022

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 7 February 2022, 1pm

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

WA7 2ES

Value of contract

£0 to £1

Procurement reference

CF-0547300D0O000000rwimUAA2

Published date

23 December 2021

Closing date

7 February 2022

Closing time

1pm

Contract start date

1 April 2022

Contract end date

31 March 2023

Contract type

Service contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.

Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome

Closing date for submissions is 7th February 2022 at 13:00

More information

Previous notice about this procurement

Regulatory Work to Secure Licence Variation for anastrozole

  • Opportunity
  • Published 23 December 2021

About the buyer

Contact name

Liz Fleetwood

Address

Rutland House
Runcorn
WA7 2ES
GB

Email

liz.fleetwood1@nhs.net